The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

August 30, 2021

Study Completion Date

May 11, 2022

Conditions
Breast Neoplasms
Interventions
DRUG

Xentuzumab

Intravenous infusion

DRUG

Placebo

Intravenous infusion

DRUG

Everolimus

Tablet

DRUG

Exemestane

Tablet

Trial Locations (54)

1090

Brussels - UNIV UZ Brussel, Jette

1200

Brussels - UNIV Saint-Luc, Brussels

2485

The Tweed Hospital, Tweed Heads

3000

UZ Leuven, Leuven

3199

Peninsula Haematology & Oncology, Frankston

8500

Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk

10960

Hematology Oncology Associates of Rockland, Nyack

11528

"General Hospital of Athens Alexandra", Athens

13009

INS Paoli-Calmettes, Marseille

15006

Hospital Teresa Herrera, A Coruña

18547

Metropolitan Hospital, Oncology Clinic, Neo Faliro, Athens

25198

Hospital Arnau de Vilanova, Lleida

28007

Hospital General Universitario Gregorio Marañón, Madrid

28034

Hospital Ramón y Cajal, Madrid

28040

Hospital Clínico San Carlos, Madrid

29010

Hospital Regional Universitario de Málaga, Málaga

30607

University Cancer and Blood Center, Athens

31059

INS Claudius Regaud IUCT-Oncopole, Toulouse

33901

Florida Cancer Specialists, Fort Myers

35128

Iov, Irccs, Padua

37203

Tennessee Oncology, PLLC, Nashville

41334

University Hospital of Larisa, Oncology Clinic, Larissa

46009

Instituto Valenciano de Oncología, Valencia

46010

Clínica Quirón de Valencia, Valencia

Hospital Clínico de Valencia, Valencia

46260

Hematology Oncology of Indiana, Indianapolis

54645

Euromedica Kyanous Stavros General Hospital, Thessaloniki

55455

University of Minnesota, Minneapolis

64132

HCA MidAmerica Division, Inc., Kansas City

69495

HOP Lyon Sud, Pierre-Bénite

71110

University General Hospital of Heraklion, Heraklion

72000

HOP Victor Hugo, Le Mans

74133

Southwestern Regional Medical Center, Tulsa

75248

INS Curie, Paris

75908

HOP Européen G. Pompidou, Paris

76104

The Center for Cancer and Blood Disorders, Fort Worth

76135

Vincentius-Diakonissen-Kliniken gAG, Karlsruhe

80131

Istituto Nazionale IRCCS Tumori Fondazione Pascale, Napoli

84000

INS Sainte Catherine, Avignon

84106

Utah Cancer Specialists Cancer Center, Salt Lake City

85224

Ironwood Cancer and Research Centers, Chandler

85338

Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear

90211

Beverly Hills Cancer Center, Beverly Hills

91054

Universitätsklinikum Erlangen, Erlangen

94158

University of California San Francisco, San Francisco

98405

Northwest Medical Specialties, PLLC, Tacoma

06510

Yale Cancer Center, New Haven

G1S 4L8

CHU de Quebec-Universite Laval Research Centre, Québec

00189

Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza, Roma

1400-038

Fundação Champalimaud,, Lisbon

2674-514

Hospital Beatriz Ângelo, Loures

4434-502

Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia

08036

Hospital Clínic de Barcelona, Barcelona

EC1A 7BE

St Bartholomew's Hospital, London

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03659136 - The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread | Biotech Hunter | Biotech Hunter